Product Description
Mechanisms of Action: mAChR Agonist,nAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: Fast Track - Liver Failure *
Approval Status: Not Approved
Approved Countries: Australia | Bangladesh | Brazil | Chile | India | Ireland | Malta | Pakistan | South Africa | Sweden | Taiwan | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Protara Therapeutics
Company Location: NEW YORK NY 10010
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Choline Deficiency|Liver Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
THRIVE-3 | P3 |
Not yet recruiting |
Liver Failure|Choline Deficiency |
2027-06-01 |